Regentis Biomaterials Secures New U.S. Patent for GelrinC Liquid Formulation Through 2038

Regentis Biomaterials Ltd. has received a new U.S. patent covering a liquid, ready-to-use formulation of its lead product GelrinC and improved production processes that eliminate organic solvents. The patent, titled "Organic Solvent Free Compositions Comprising Protein-Polymer Conjugates and Uses Thereof," provides intellectual property protection for the company's technology through 2038.

The liquid formulation of GelrinC is designed to simplify surgical procedures and improve patient experience by conforming precisely to cartilage wounds before being cured with UV light to form a temporary elastomeric implant. This advancement represents a significant step in orthopedic treatment innovation, particularly for the approximately 470,000 annual cases of cartilage knee repair in the U.S. where no off-the-shelf treatment is currently available.

According to Executive Chairman Dr. Ehud Geller, this patent milestone coincides with the company surpassing 50% enrollment in its pivotal U.S. Food and Drug Administration clinical trial for knee cartilage repair. The timing suggests Regentis is making substantial progress toward potential regulatory approval and commercialization of its technology.

The patent covers not only the liquid formulation but also improved production processes that eliminate the use of organic solvents, which could enhance manufacturing efficiency and potentially reduce production costs. This technological advancement aligns with the company's mission to develop innovative tissue repair solutions that restore health and enhance quality of life through its Gelrin platform technology.

Regentis' Gelrin platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue including inflamed cartilage and bone. GelrinC, the company's lead product, is a cell-free, off-the-shelf hydrogel that erodes and resorbs in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process.

The extended patent protection through 2038 provides Regentis with substantial intellectual property security as it advances through clinical trials and toward potential market entry. This protection could create barriers to entry for competitors and enhance the company's valuation and investment appeal. For more information about Regentis Biomaterials, visit https://www.regentis.co.il/.

This development has implications for the broader regenerative medicine industry, particularly in orthopedics where cartilage repair represents a significant unmet medical need. The advancement of off-the-shelf solutions like GelrinC could potentially reduce surgical complexity, improve patient outcomes, and address a substantial market opportunity. The progress in clinical trials and strengthened intellectual property position Regentis as a company to watch in the evolving field of tissue regeneration technologies.